Kamada Ltd. announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S. for KEDRAB(R) (R babies Immune Globulin [Human), which is indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. The current agreement now extends through March 2026, and the companies are in discussions to potentially further expand the scope of the collaboration.